AtriCure (NASDAQ:ATRC) Price Target Raised to $66.00 at Canaccord Genuity Group

AtriCure (NASDAQ:ATRC) had its price target upped by Canaccord Genuity Group from $61.00 to $66.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the medical device company’s stock.

ATRC has been the topic of several other research reports. JPMorgan Chase & Co. upped their price target on shares of AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Tuesday. Oppenheimer increased their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JMP Securities restated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $51.00 price objective on shares of AtriCure in a research report on Thursday. Finally, UBS Group lifted their target price on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.56.

AtriCure Trading Down 6.5 %

Shares of ATRC opened at $39.59 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -47.70 and a beta of 1.46. The stock has a fifty day moving average price of $35.52 and a two-hundred day moving average price of $31.17. AtriCure has a 52-week low of $18.94 and a 52-week high of $43.11.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI acquired a new stake in shares of AtriCure during the third quarter worth $28,000. Heck Capital Advisors LLC bought a new position in AtriCure during the fourth quarter worth about $60,000. Venturi Wealth Management LLC grew its position in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after buying an additional 2,100 shares during the period. KBC Group NV increased its stake in shares of AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after acquiring an additional 932 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of AtriCure in the 4th quarter valued at approximately $89,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.